AC2993 (synthetic exendin-4)
In preclinical studies to date:
- Biologically active via non-injectable routes
- Conversion of non-insulin producing cells into insulin producing cells
In clinical studies to date:
- Stimulated insulin secretion
- Reduced post-meal glucagon
- Reduced blood glucose levels